Wu Junhao, Wang Yingwei, Liao Taiping, Rao Zijuan, Gong Weidong, Ou Lei, Chen Yue, Zhang Chunyin
Department of Nuclear Medicine, The Affiliated Hospital, Southwest Medical University, Luzhou, China.
Nuclear Medicine and Molecular Imaging Key Laboratory of Sichuan Province, Luzhou, China.
Front Oncol. 2021 Sep 17;11:737827. doi: 10.3389/fonc.2021.737827. eCollection 2021.
The present retrospective analysis sought to compare the relative diagnostic efficacy of [Ga]Ga-DOTA-FAPI-04 to that of [F]FDG PET/CT as a means of detecting bone metastases in patients with a range of cancer types.
In total, 30 patients with bone metastases associated with different underlying malignancies were retrospectively enrolled. All patients had undergone [Ga]Ga-DOTA-FAPI-04 and [F]FDG PET/CT, and the McNemar test was used to compare the relative diagnostic performance of these two imaging modalities. The maximum standard uptake value (SUVmax) was used to quantify radiotracer uptake by metastatic lesions, with the relative uptake associated with these two imaging strategies being compared the Mann-Whitney U test. The cohort was further respectively divided into two (osteolytic and osteoblastic bone metastases) and three clinical subgroups (lung cancer, thyroid cancer, and liver cancer).
[Ga]Ga-DOTA-FAPI-04 PET/CT was found to be significantly more sensitive as a means of diagnosing bone metastases relative to [F]FDG PET/CT ([109/109] 100% [89/109] 81.7%; P< 0.01), consistent with the significantly increased uptake of [Ga]Ga-DOTA-FAPI-04 by these metastatic lesions relative to that of [F]FDG (n=109, median SUVmax, 9.1 . 4.5; P< 0.01). [Ga]Ga-DOTA-FAPI-04 accumulation was significantly higher than that of [F]FDG in both osteolytic (n=66, median SUVmax, 10.6 6.1; P < 0.01), and osteoblastic metastases (n=43, median SUVmax, 7.7 3.7; P < 0.01). [Ga]Ga-DOTA-FAPI-04 uptakes were significantly higher than that of [F]FDG in bone metastases from lung cancer (n = 62, median SUVmax, 10.7 5.2; P < 0.01), thyroid cancer (n = 18, median SUVmax, 5.65 2.1; P < 0.01) and liver cancer (n = 12, median SUVmax, 5.65 3.05; P < 0.01). However, [Ga]Ga-DOTA-FAPI-04 detected 10 false-positive lesions, while only 5 false-positive were visualized by [F]FDG PET/CT.
[Ga]Ga-DOTA-FAPI-04 PET/CT exhibits excellent diagnostic performance as a means of detecting bone metastases, and is superior to [F]FDG PET/CT in this diagnostic context. Furthermore, [Ga]Ga-DOTA-FAPI-04 tracer uptake levels are higher than those of [F]FDG for most bone metastases. However, owing to the potential for false-positive bone lesions, it is critical that physicians interpret all CT findings with caution to ensure diagnostic accuracy.
本回顾性分析旨在比较[镓]Ga-DOTA-FAPI-04与[氟]FDG PET/CT在检测多种癌症类型患者骨转移方面的相对诊断效能。
总共回顾性纳入了30例与不同潜在恶性肿瘤相关的骨转移患者。所有患者均接受了[镓]Ga-DOTA-FAPI-04和[氟]FDG PET/CT检查,并使用McNemar检验比较这两种成像方式的相对诊断性能。采用最大标准摄取值(SUVmax)对转移病灶的放射性示踪剂摄取进行量化,并使用Mann-Whitney U检验比较这两种成像策略的相对摄取情况。该队列进一步分别分为两个亚组(溶骨性和成骨性骨转移)以及三个临床亚组(肺癌、甲状腺癌和肝癌)。
发现[镓]Ga-DOTA-FAPI-04 PET/CT作为诊断骨转移的手段,相对于[氟]FDG PET/CT具有显著更高的敏感性([109/109] 100% [89/109] 81.7%;P<0.01),这与这些转移病灶对[镓]Ga-DOTA-FAPI-04的摄取相对于[氟]FDG显著增加一致(n = 109,SUVmax中位数,9.1 对 4.5;P<0.01)。在溶骨性转移(n = 66,SUVmax中位数,10.6对6.1;P<0.01)和成骨性转移(n = 43,SUVmax中位数,7.7对3.7;P<0.01)中,[镓]Ga-DOTA-FAPI-04的积聚均显著高于[氟]FDG。在肺癌(n = 62,SUVmax中位数,10.7对5.2;P<0.01)、甲状腺癌(n = 18,SUVmax中位数,5.65对2.1;P<0.01)和肝癌(n = 12,SUVmax中位数,5.65对3.05;P<0.01)的骨转移中,[镓]Ga-DOTA-FAPI-04的摄取也显著高于[氟]FDG。然而,[镓]Ga-DOTA-FAPI-04检测到10例假阳性病灶,而[氟]FDG PET/CT仅显示5例假阳性。
[镓]Ga-DOTA-FAPI-04 PET/CT作为检测骨转移的手段具有出色的诊断性能,在这种诊断背景下优于[氟]FDG PET/CT。此外,对于大多数骨转移,[镓]Ga-DOTA-FAPI-04示踪剂摄取水平高于[氟]FDG。然而,由于存在骨病变假阳性的可能性,医生谨慎解读所有CT结果以确保诊断准确性至关重要。